Neil A. O’Brien - Concepedia

Author

Neil A. O’Brien

University of California, Los Angeles ORCID

Also Known As

N A O'Brien, N O'Brien, N. A. O’Brien, N. O'Brien, NEIL O'BRIEN, Neil A O'Brien, Neil A O’Brien, Neil A. O'Brien, Neil A. O'brien, Neil A. O’Brien

375

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles St. Vincent's University Hospital Dublin City University University College Dublin Harvard University

About

Neil A. O’Brien is an author at University of California, Los Angeles specializing in medicine, breast cancer, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	1K
2	Cell Biology	12	12	981
3	Immunology	1	1	27
4	Obstetrics	1	1	72
5	Pathology	1	1	37

Neil A. O’Brien

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib Neil A. O’Brien, Brigid C. Browne, Lucy Chow, Molecular Cancer Therapeutics Radiation OncologyBreast OncologySignal TransductionHer2-amplified Cell LinesSignaling Pathway	2010	334
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Oncotarget Trastuzumab ResistanceBreast OncologyTrastuzumab-sensitive Breast CancerMedicinePharmacology	2013	162
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Neil A. O’Brien, Martina S.J. McDermott, Dylan Conklin, Breast Cancer Research	2020	150
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT Neil A. O’Brien, K McDonald, Tong Luo, Clinical Cancer Research	2014	114
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer Neil A. O’Brien, Dylan Conklin, Richard P. Beckmann, Molecular Cancer Therapeutics	2018	103
Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Ondrej Kalous, Dylan Conklin, Amrita Desai, Molecular Cancer Therapeutics Human EgfBreast OncologyOncologyIrreversible Pan-her InhibitorMedicine	2012	84
Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells Gottfried E. Konecny, Teodora Kolarova, Neil A. O’Brien, Molecular Cancer Therapeutics Tumor BiologyOncologyEndocrine-related CancerFgfr InhibitorsMedicine	2013	72
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Molecular Cancer Therapeutics	2013	68
Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance Rosalía I. Cordo Russo, Wendy Béguelin, María C. Díaz Flaqué, Oncogene Trastuzumab ResistanceBreast OncologyMedicineCancer GrowthBreast Cancer	2014	52
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response Sara A. Hurvitz, Ondrej Kalous, Dylan Conklin, Breast Cancer Research and Treatment Breast OncologyMedicinePharmacologyMtor Inhibitor EverolimusBreast Cancer	2015	51

Page 1